News
-
Indian contract research and manufacturing company Kemwell Biopharma has acquired North Carolina-based CRO Cirrus Pharmaceuticals, which offers development services for inhaled and nasal drugs among other dosage forms. Cirrus also provides analytical services for OINDPs.… Read more . . .
-
Novartis has announced that its Ultibro Breezhaler indacaterol/glycopyrronium DPI (QVA149) has gotten a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of COPD. The company filed an… Read more . . .
-
Pulmatrix has initiated a Phase 1B study of its PUR0200, an inhaled LAMA for the treatment of COPD, the company says. PUR0200 is a lactose-free formulation created using the company’s iSPERSE particle engineering technology. Pulmatrix… Read more . . .
-
Mylan has announced that the United States District Court for the Northern District of West Virginia granted a Mylan motion for partial summary judgment and found that Teva’s generic formoterol fumarate inhalation solution infringes US… Read more . . .
-
Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx’s Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from… Read more . . .
-
MDI component manufacturer Presspart has hired Sameer Kunte as its new Customer Services Manager for India, the company said. Kunte has extensive experience with OINDP device development and has worked previously for 3M, Dr. Reddy’s,… Read more . . .
-
The final article in a 3-part series . . . Read more Read more . . .
-
Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company… Read more . . .
-
GlaxoSmithKline and Theravance have withdrawn the application for their fluticasone furoate/vilanterol DPI for the treatment of COPD from the Japanese New Drug Application (JNDA) for the drug, the companies say. Review of the JNDA, which… Read more . . .
-
GlaxoSmithKline has announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved for the treatment of COPD in Canada. GlaxoSmithKline Inc. President Paul Lirette said, “For over forty years, GlaxoSmithKline has been at the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.